Casdin Capital LLC Invests $1.12 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Casdin Capital LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 165,323 shares of the company's stock, valued at approximately $1,118,000.

A number of other hedge funds have also modified their holdings of the company. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $27,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on RXRX. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, Morgan Stanley lowered their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock traded down $0.06 on Friday, reaching $4.33. The stock had a trading volume of 14,766,105 shares, compared to its average volume of 12,910,924. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -2.83 and a beta of 0.99. The firm's 50-day moving average is $5.53 and its two-hundred day moving average is $6.66.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.39) earnings per share. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.